UY26969A1 - Combinaciones farmacéuticas - Google Patents

Combinaciones farmacéuticas

Info

Publication number
UY26969A1
UY26969A1 UY26969A UY26969A UY26969A1 UY 26969 A1 UY26969 A1 UY 26969A1 UY 26969 A UY26969 A UY 26969A UY 26969 A UY26969 A UY 26969A UY 26969 A1 UY26969 A1 UY 26969A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical combinations
nif
thrombolytic
neuroprotective
favors
Prior art date
Application number
UY26969A
Other languages
English (en)
Inventor
Christopher John Brearley
Paul Butler
Suresh Babubhai Chahwala
Michael Chopp
Michael Krams
Michael Looby
Fiona Macintyre
Andrew Brian Mcelroy
Aileen Dorothy Mcharg
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY26969A1 publication Critical patent/UY26969A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta invención se refiere, entre otros, a métodos para tratar condiciones patofisiológicas que implican a los neutrófilos, que comprenden administrar a un paciente que necesite tal tratamiento una terapia de combinación que comprende al menos un factor inhibidor de los neutrófilos (NIF) y al menos otro agente que protege a las neuronas de la agresión tóxica, inhibe la reacción inflamatoria después de una lesión cerebral o favorece la reperfusión cerebral (esto es, agentes neuroprotectores o trombolíticos/fibrinolíticos), o una serie de sus sales farmacéuticamente aceptables.
UY26969A 2000-10-17 2001-10-16 Combinaciones farmacéuticas UY26969A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0025473.0A GB0025473D0 (en) 2000-10-17 2000-10-17 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
UY26969A1 true UY26969A1 (es) 2002-06-20

Family

ID=9901490

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26969A UY26969A1 (es) 2000-10-17 2001-10-16 Combinaciones farmacéuticas

Country Status (13)

Country Link
US (1) US20020098179A1 (es)
AP (1) AP2001002295A0 (es)
AR (1) AR034698A1 (es)
AU (1) AU2002210795A1 (es)
DO (1) DOP2001000266A (es)
GB (1) GB0025473D0 (es)
GT (1) GT200100207A (es)
HN (1) HN2001000232A (es)
PA (1) PA8530701A1 (es)
PE (1) PE20020536A1 (es)
TN (1) TNSN01142A1 (es)
UY (1) UY26969A1 (es)
WO (1) WO2002032446A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20030219431A1 (en) * 2002-05-24 2003-11-27 Empire Pharmaceuticals, Inc. Treatment of neuronal and neurological damage associated with spinal cord injury
CN1310949C (zh) * 2003-01-13 2007-04-18 重庆富进生物医药有限公司 具有抑制白细胞功能和凝血酶活性的双功能嵌合蛋白
CA2426115A1 (en) * 2003-04-18 2004-10-18 Victor Gurewich Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots
CA2578224A1 (en) * 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
US20070167419A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
AU2006335153B2 (en) 2006-01-05 2012-03-15 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
CN101245110B (zh) * 2007-02-16 2010-09-15 鲁南制药集团股份有限公司 重组中性粒细胞抑制因子和水蛭原嵌合蛋白及其药物组合物
JP2010532383A (ja) * 2007-07-02 2010-10-07 エッセンシャリス，インク． カリウムａｔｐチャネル開口薬の塩およびその使用
AR068914A1 (es) * 2007-10-18 2009-12-16 Paion Deutschland Gmbh Uso de un activador de plasminogeno para la preparacion de un medicamento para el tratamiento de apoplejia
JP6005514B2 (ja) 2009-06-10 2016-10-12 ノノ インコーポレイテッド 神経疾患の治療のためのモデル系及び治療計画
US10064910B2 (en) * 2011-06-24 2018-09-04 Nono Inc. Combination therapy for ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
WO2016073514A2 (en) 2014-11-03 2016-05-12 Thrombolytic Science, Llc Methods and compositions for safe and effective thrombolysis
US10336827B2 (en) 2015-10-29 2019-07-02 Wayne State University Compositions and methods to treat solid tumors
EP3411022B1 (en) * 2016-02-01 2021-09-15 Emory University Particles for targeted delivery and uses in managing bleeding or blood clotting
WO2018232305A1 (en) 2017-06-16 2018-12-20 Thrombolytic Science, Llc Methods and compositions for thrombolysis
CN116669757A (zh) * 2020-11-17 2023-08-29 泰伦基国际有限公司 一种提高bdnf水平的方法和药物
WO2022261282A1 (en) * 2021-06-09 2022-12-15 Proniras Corporation Methods of treating or preventing conditions associated with opiate withdrawal or opiate relapse

Also Published As

Publication number Publication date
PE20020536A1 (es) 2002-06-20
HN2001000232A (es) 2002-04-22
AP2001002295A0 (en) 2001-12-31
DOP2001000266A (es) 2002-05-31
TNSN01142A1 (fr) 2005-11-10
AU2002210795A1 (en) 2002-04-29
US20020098179A1 (en) 2002-07-25
WO2002032446A3 (en) 2002-07-11
GB0025473D0 (en) 2000-11-29
AR034698A1 (es) 2004-03-17
WO2002032446A2 (en) 2002-04-25
PA8530701A1 (es) 2003-06-30
GT200100207A (es) 2002-08-19

Similar Documents

Publication Publication Date Title
UY26969A1 (es) Combinaciones farmacéuticas
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
AR035533A1 (es) Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la
PA8606201A1 (es) DERIVADOS DE PIRROLO[3,4-c) PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA, PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN
NO20024814D0 (no) Terapeutiske kombinasjoner av antihypertensive og antiangiogene midler
AR038535A1 (es) Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
HUP0203160A2 (hu) Plakk ruptura kialakulásának megakadályozása ACAT-inhibitorok alkalmazásával
ECSP066516A (es) Formulaciones farmacéuticas, procedimientos y pautas de dosificación para el tratamiento y prevención de síndromes coronarios agudos
NO20012896L (no) Fremgangsmåte for behandling av cerebral ischemi og anvendelse av erytropoietin eller erytropoietinderivater forbehandling av cerebral ischemi
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
MY119375A (en) Treatment of tinnitus using neuroprotective agents
ES2154693T3 (es) Combinacion de sustancias inductoras de necrosis con sustancias que son activadas por necrosis, para la terapia selectiva de tumores y enfermedades inflamatorias.
CO5590913A2 (es) Terapia de combinacion antivirica
NO20061184L (no) Fremgangsmater og blandinger for behandling av herpes-infeksjoner
CY1119190T1 (el) Χρηση αναστολεων της il-18 για αγωγη ή προληψη βλαβων του κνς
ES2180933T3 (es) Inhibidor de la serina-proteasa.
CL2023002746A1 (es) Inhibidores de la línea 1 para tratar enfermedades del snc y sistémicas
PL368971A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
PA8552301A1 (es) Metodo para el tratamiento de insomnio primario
BR0211836A (pt) Inibidor de anidrase carbÈnica
ES2165034T3 (es) Agentes terapeuticos que contienen ebselen contra el asma.
ES2155223T3 (es) 1-naftoilguanidinas sustituidas, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
MX9305106A (es) Metodos para el tratamiento de cancer.
AR002968A1 (es) Uso de hirudina y acido acetilsalicilico para la preparacion de un medicamento para tratar un infarto de miocardio agudo en pacientes nosometidos a tratamiento trombolitico y una composicion farmaceutica.
DK1235573T3 (da) Kombination af riluzol og gabapentin og anvendelse deraf som medikament ved behandling af motorneuronsygdomme

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150424